* Syros Pharmaceuticals Inc reported a quarterly adjusted loss of 16 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.43. The mean expectation of five analysts for the quarter was for a loss of 72 cents per share. Wall Street expected results to range from -78 cents to -65 cents per share.
* Reported revenue was zero; analysts expected $450.00 thousand.
* Syros Pharmaceuticals Inc's reported EPS for the quarter was a loss of 16 cents.
* The company reported a quarterly loss of $6.4 million.
* Syros Pharmaceuticals Inc shares had risen by 16.7% this quarter and lost 67.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 1.1% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Syros Pharmaceuticals Inc is 10.00 This summary was machine generated from LSEG data November 1 at 03:30 a.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.72 -0.16 Beat
Jun. 30 2024 -0.77 -0.59 Beat
Mar. 31 2024 -0.87 -0.10 Beat
Dec. 31 2023 -1.14 -2.18 Missed